Leprosy is a complex disease from a clinical, histopathological and molecular point of view. During the course of the disease, reactional phenomena often appear which may aggravate the disease, causing permanent sequelae. Two types of reaction phenomenon occur in leprosy and are called type 1 (T1R) and type 2 (T2R). The pathophysiological mechanisms of both reactions are poorly understood, the drugs (corticosteroids and thalidomide) used to treat them are not very specific and can cause important side effects and, so far, these episodes cannot be prevented. New studies are important to identify biomarkers that would help to elucidate the pathophysiology of leprosy reactions and that may be used as therapeutic targets in the treatment and prevention of leprosy reactions
In this research topic, we aim to focus on new discoveries in leprosy reactions. The objective is to publish different topics on original research, ranging from new treatment proposals with pre-existing drugs, the identification of biomarkers that may be useful in the development of new treatment modalities or prevention of reactions, as well as new technologies that can reduce the sequelae caused by leprosy reactions
We encourage the submission of clinical, translational and basic research on leprosy reactions (T1R and T2R). Both original research articles and reviews focusing on, but not limited to, the following topics:
• Biomarkers, transcriptomic or proteomic profiles that correlate with the reactional phenomena in leprosy.
• Discovery and development of new drug targets for the treatment or prevention of reactions (T1R and T2R).
• Clinical studies evaluating the risks of triggering reactional phenomena during or after conventional leprosy treatment.
• Serum or tissue markers that may be related to reactions.
• New therapeutic proposals, with commercially known drugs or new drugs, for the prevention or treatment of leprosy reactions.
• New technologies for the diagnosis and treatment of type 1 (T1R) and type 2 (T2R) reactions.
Leprosy is a complex disease from a clinical, histopathological and molecular point of view. During the course of the disease, reactional phenomena often appear which may aggravate the disease, causing permanent sequelae. Two types of reaction phenomenon occur in leprosy and are called type 1 (T1R) and type 2 (T2R). The pathophysiological mechanisms of both reactions are poorly understood, the drugs (corticosteroids and thalidomide) used to treat them are not very specific and can cause important side effects and, so far, these episodes cannot be prevented. New studies are important to identify biomarkers that would help to elucidate the pathophysiology of leprosy reactions and that may be used as therapeutic targets in the treatment and prevention of leprosy reactions
In this research topic, we aim to focus on new discoveries in leprosy reactions. The objective is to publish different topics on original research, ranging from new treatment proposals with pre-existing drugs, the identification of biomarkers that may be useful in the development of new treatment modalities or prevention of reactions, as well as new technologies that can reduce the sequelae caused by leprosy reactions
We encourage the submission of clinical, translational and basic research on leprosy reactions (T1R and T2R). Both original research articles and reviews focusing on, but not limited to, the following topics:
• Biomarkers, transcriptomic or proteomic profiles that correlate with the reactional phenomena in leprosy.
• Discovery and development of new drug targets for the treatment or prevention of reactions (T1R and T2R).
• Clinical studies evaluating the risks of triggering reactional phenomena during or after conventional leprosy treatment.
• Serum or tissue markers that may be related to reactions.
• New therapeutic proposals, with commercially known drugs or new drugs, for the prevention or treatment of leprosy reactions.
• New technologies for the diagnosis and treatment of type 1 (T1R) and type 2 (T2R) reactions.
